Provided by Tiger Trade Technology Pte. Ltd.

HARBOR HEALTH CARE ETF

32.72
+0.28570.88%
Post-market: 32.720.00000.00%16:10 EDT
Volume:2K
Turnover:74.53K
Market Cap:41.71M
PE:- -
High:32.81
Open:32.81
Low:32.72
Close:32.43
52wk High:35.61
52wk Low:27.50
Shares:1.28M
Float Shares:1.28M
Volume Ratio:0.61
T/O Rate:0.18%
Dividend:0.08
Dividend Rate:0.23%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ascendis Pharma (ASND), Lakefront Biotherapeutics (LKFT) and 10x Genomics (TXG)

TIPRANKS
·
Sep 28

Eli Lilly price target raised to $1,500 from $1,400 at JPMorgan

TIPRANKS
·
Sep 28

Xilio Therapeutics Names Yariv Houvras Chief Medical Officer

Reuters
·
Sep 28

Lilly Launches Initiative to Expand Diabetes, Obesity Drug Access

MT Newswires Live
·
Sep 28

Eli Lilly launches ‘Lilly Change the Course Commitment’

TIPRANKS
·
Sep 28

Eli Lilly - to Register Diabetes and Obesity Medicines in Lmics and Expand Access

THOMSON REUTERS
·
Sep 28

Eli Lilly - Aims to Treat Equal Number of Patients in Lmics and High-Income Countries by 2040

THOMSON REUTERS
·
Sep 28

Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M

TIPRANKS
·
Sep 28

Ascendis Pharma Price Target Maintained with a $300.00/Share by Cantor Fitzgerald

Dow Jones
·
Sep 28

JPMorgan Adjusts Price Target on Eli Lilly to $1,500 From $1,400, Maintains Overweight Rating

MT Newswires Live
·
Sep 28

Eli Lilly's Olumiant Gets FDA Approval for Severe Alopecia Areata in Adolescents

MT Newswires Live
·
Sep 28

EBR Systems advances FDA approval process for new WiSE manufacturing site

TIPRANKS
·
Sep 28

Nektar selloff on trial brings ‘strong entry point,’ says BTIG

TIPRANKS
·
Sep 28

Eli Lilly Gets Expanded Label Approval from FDA for Alopecia Drug

Dow Jones
·
Sep 26

FDA Approves Lilly's Olumiant (Baricitinib) for Pediatric Patients 12 Years of Age and Older with Severe Alopecia Areata

THOMSON REUTERS
·
Sep 26

Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case

MT Newswires Live
·
Sep 26

Sector Update: Healthcare Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Sep 25

Novo Bets on Next Chapter While Eli Lilly Extends Its GLP-1 Dominance

Deep News
·
Sep 25

Legend Biotech Says Five-Year Carvykti Data Show 50% of Patients Remained Progression-Free and Alive

MT Newswires Live
·
Sep 25

Legend Biotech Reports Five-Year CARVYKTI Survival Data in Earlier-Line Myeloma

TIPRANKS
·
Sep 25